Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 18 · below the Ichimoku cloud · RSI 33 · MACD above its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.5M | 0.00% | 110.52K | −19% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a KRRO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 13, 2026 | Formela Jean FrancoisDirector | Sale at price 13.99 - 14.12 per share. | 48.7K | $686.18K |
| Sep 10, 2026 | Dolan OliverOfficer | Sale at price 13.72 per share. | 5 | $69 |
| Sep 8, 2026 | Dolan OliverOfficer | Sale at price 13.51 - 13.60 per share. | 7.4K | $99.37K |
| Aug 25, 2026 | Formela Jean FrancoisDirector | Sale at price 13.96 per share. | 300 | $4.19K |
| Aug 18, 2026 | Formela Jean FrancoisDirector | Sale at price 14.00 per share. | 28.5K | $398.55K |
| Aug 10, 2026 | Formela Jean FrancoisDirector | Sale at price 13.96 per share. | 2.1K | $29.92K |
| Aug 9, 2026 | Lynx1 Capital Management LpBeneficial Owner of more than 10% of a Class of Security | Purchase at price 11.40 - 13.19 per share. | 6.7K | $78.81K |
| Aug 3, 2026 | Aiyar Ram Ph.D.Chief Executive Officer | Sale at price 10.84 per share. | 5.8K | $62.92K |
| Jul 14, 2026 | Chappell ToddChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 7.5K | — |
| Jul 14, 2026 | Cerio JeffreyGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 6.5K | — |
| Jul 14, 2026 | Dolan OliverOfficer | Stock Award(Grant) at price 0.00 per share. | 5.5K | — |
| Jul 14, 2026 | Vincent Loic A.Officer | Stock Award(Grant) at price 0.00 per share. | 7.5K | — |
| Jul 5, 2026 | Formela Jean FrancoisDirector | Sale at price 13.96 - 14.03 per share. | 110K | $1.54M |
| Jun 23, 2026 | Formela Jean FrancoisDirector | Sale at price 13.95 - 14.98 per share. | 171.4K | $2.46M |
| Jun 15, 2026 | Chappell ToddChief Operating Officer | Sale at price 10.83 per share. | 3.2K | $34.31K |
| Jun 15, 2026 | Cerio JeffreyGeneral Counsel | Sale at price 10.83 per share. | 6.6K | $71.58K |
| Jun 15, 2026 | Dolan OliverOfficer | Sale at price 10.83 per share. | 3.4K | $36.64K |
| Jun 15, 2026 | Vincent Loic A.Officer | Sale at price 10.83 per share. | 3.4K | $37.02K |
| May 28, 2026 | Aiyar Ram Ph.D.Chief Executive Officer | Sale at price 12.98 per share. | 15.2K | $196.67K |
| May 27, 2026 | Formela Jean FrancoisDirector | Sale at price 13.95 per share. | 2.9K | $39.90K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 66.4 | -9.0 | -6.7 | 19.2 | -0.6 | -1.7 | -21.3 | 20.4 | -20.7 | -10.4 | +10.9% | ||
| 2025 | -10.4 | -26.5 | -30.6 | 2.0 | -35.7 | 9.4 | 19.8 | 54.3 | 107.5 | -14.6 | -86.1 | 40.5 | −79.0% |
| 2024 | 6.0 | -4.9 | 86.3 | -36.9 | -9.7 | -34.0 | 37.5 | 2.5 | -30.0 | 72.1 | -9.5 | -26.9 | −20.6% |
| 2023 | 17.9 | -85.0 | -26.0 | -20.7 | -12.3 | -1.1 | 47.7 | -6.1 | -22.9 | -35.1 | 249.2 | 14.4 | −75.1% |
| 2022 | 4.7 | -47.1 | -25.4 | -38.7 | -13.8 | 33.9 | 33.3 | 3.0 | -13.1 | -3.4 | 28.3 | 73.4 | −25.0% |
| 2021 | 10.6 | 26.2 | -80.7 | 22.2 | -23.8 | 12.5 | -16.4 | -7.3 | -8.5 | -11.0 | -18.8 | 0.6 | −85.5% |
| 2020 | 36.4 | -9.4 | -17.8 | -10.7 | 16.7 | 25.3 | -9.1 | -8.5 | -0.7 | 13.9 | 31.2 | 22.9 | +101.1% |
| 2019 | 16.0 | 5.0 | +21.7% |
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Buy / hold / sell counts